Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.47 |
| ▸ | CA1 | P00915 | 11/20 | 0.47 |
| ▸ | CA12 | O43570 | 10/20 | 0.46 |
| ▸ | CA9 | Q16790 | 9/20 | 0.46 |
| ▸ | LOX | P28300 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871322 | 0.86 | SMN1; SMN2 (0.47) | LOXF2PRSS1PRSS2PRSS3 | |
| SCHEMBL3232938 | 0.84 | LOX (0.56) | CA2CA1CA12CA9LOX | |
| SCHEMBL15281239 | 0.82 | KMT2A (0.50) | — | |
| SCHEMBL5774662 | 0.81 | CA2 (0.54) | CA2CA1CA12CA9CA6 | |
| SCHEMBL7015512 | 0.80 | SMN1; SMN2 (0.57) | — | |
| SCHEMBL4999299 | 0.79 | KMT2A (0.56) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL31426393 | 0.79 | KMT2A (0.56) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL2300229 | 0.78 | CA1 (0.70) | CA2CA1CA12CA9LOX | |
| SCHEMBL8271457 | 0.78 | PARP1 (0.54) | CA2CA1 | |
| SCHEMBL12350284 | 0.78 | PBRM1 (0.49) | F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20130296551-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | DAIICHI SANKYO CO LTD (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2463268-B1 | 4-(Aminomethyl)benzoic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds | DAIICHI SANKYO CO LTD (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-8507714-B2 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8362063-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| EP-1820798-B1 | 7-MEMBERED RING COMPOUND, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | DAIICHI SANKYO CO LTD (JP) | 2012-08-22 | — | — | EP | disclosed |
| US-8049006-B2 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20110166342-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-7888348-B2 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| EP-2268612-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | ASUBIO PHARMA CO., LTD (JP) | 2009-10-08 | — | — | US | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| US-20090111796-A1 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-2025672-A1 | SEVEN-MEMBERED RING COMPOUND, PRODUCTION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Asubio Pharma Co., Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1820798-A1 | 7-MEMBERED RING COMPOUND, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | Asubio Pharma Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | MMP11, MMP10, MMP9 | CA2 1123/4885CA1 2747/4885CA12 700/4885 |
| US-20090111796-A1 | 7-membered ring compound and method of production and pharmaceutical application thereof | CMA1, CPA3, SI | CA2 187/4885CA1 418/4885CA12 352/4885 |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | MMP11, MMP10, MMP9 | CA2 1123/4885CA1 2747/4885CA12 700/4885 |
| US-20130296551-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | CA2 187/4885CA1 418/4885CA12 352/4885 |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | CA2 187/4885CA1 418/4885CA12 352/4885 |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | CA2 1073/4885CA1 2740/4885CA12 686/4885 |
| US-20110166342-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | CA2 187/4885CA1 418/4885CA12 352/4885 |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | CA2 1073/4885CA1 2740/4885CA12 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.